MetaVia Inc., was incorporated in October 2014 under the laws of the State of Delaware. The company is a clinical-stage biotechnology company focused on the development of novel drugs for the treatment of cardiovascular and metabolic diseases, with major projects targeting metabolic dysfunction-related steatohepatitis and obesity. Its R&D pipeline includes GPR119 agonist vanoglipel and oxyntomodulin analog dual agonist DA-1726.
